Renalytix Plc logo

Renalytix Plc(OTC) RNLX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-99%
1 Year-43%
1 Month-14%
N/A
Renalytix Plc last closing stock price
MetricPriceDate
Last closeUSD 3.502026-10-14
Renalytix Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.89%USD 3.802026-10-07
1 month-14%USD 4.072026-09-14
3 month+88.68%USD 1.862026-07-16
Year to date-3.31%USD 3.622025-12-31
1 year-42.62%USD 6.102025-10-14
3 year-87.93%USD 29.002023-10-13
5 year-99.43%USD 616.502021-10-15
Since inception-98.96%USD 337.502020-07-17

Renalytix Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.35M

Net Income (TTM)

-$28.03M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 30, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Renalytix Plc

Renalytix Plc is a healthcare technology company focused on developing artificial intelligence-driven diagnostic tools for kidney diseases. Established in 2018, the company aims to improve patient outcomes through its innovative product, KidneyIntelX, which leverages AI algorithms to assess kidney health.

Products and Services
  • KidneyIntelX: AI-powered diagnostic system for kidney disease
  • Collaborations with healthcare institutions for advanced kidney disease diagnosis
  • Biomarker-based products for kidney disease prediction
Growth Outlook
  • Strategic partnerships with leading health systems enhance market reach
  • Increasing demand for AI-driven diagnostics in healthcare
  • Focus on expanding product offerings to address unmet medical needs
Financial Highlights
  • Recent quarterly revenue of $522,000, showing potential for growth
  • Trailing twelve months (TTM) revenue of $2.4 million, indicating steady performance
  • Cash reserves of $909,000 as of September 30, 2024, supporting operational needs
Renalytix Plc operates in the rapidly evolving healthcare information services sector, with a strong emphasis on artificial intelligence. The company's flagship product, KidneyIntelX, is designed to provide healthcare professionals with critical insights into kidney health, enabling timely interventions. The strategic collaborations with renowned institutions like Mount Sinai Health System and Joslin Diabetes Center further bolster the company's credibility and market presence. The growth outlook for Renalytix is promising, driven by the increasing adoption of AI technologies in healthcare and the company's commitment to expanding its product portfolio. Recent financial data reflects a revenue of $522,000 for the latest quarter, alongside a TTM revenue of $2.4 million, suggesting a solid foundation for future growth. With cash reserves of $909,000, the company is positioned to navigate its operational challenges while pursuing its innovative goals.
AI Generated • Sep 21, 2026

Industry

Health Care Technology

Employees

46

CEO

James Renwick McCullough, MBA

Headquarters

New York City, NY 10036, US

RNLX Financials

Key Financial Metrics (TTM)

Gross Margin

6.82%

Operating Margin

-1293.49%

Net Income Margin

-1461.60%

Return on Equity

-631.25%

Return on Capital

-4347.72%

Return on Assets

-419.67%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$299.00K

Operating Income

-$24.09M

EBITDA

-$24.44M

Operating Cash Flow

-$24.44M

Capital Expenditure

-$4.00K

Free Cash Flow

-$24.45M

Cash & ST Invst.

$909.00K

Total Debt

$8.25M

Renalytix Plc Performance Analysis

Renalytix Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 2,959,160N/A
20232023-06-30USD 3,415,70215.4%
20242024-06-30USD 2,301,930-32.6%
20252025-06-30USD 3,013,87430.9%
Renalytix Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-12-3154.5%
Q32024-03-31-24.5%
Q42024-06-309.5%
Q12024-09-30-10.9%
Renalytix Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -30.96N/A
20232023-06-30USD -27.84-10.1%
20242024-06-30USD -21.05-24.4%
20252025-06-30USD -3.73-82.3%
Renalytix Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-12-3118.2%
Q32024-03-3111.9%
Q42024-06-3035.4%
Q12024-09-3021.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$522.00K

+13.7%

Gross Profit

$100.00K

+332.6%

Gross Margin

19.16%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

102

N/A

Net Income

-$4.73M

+53.4%

EBITDA

-$4.03M

+54.0%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$909.00K

-93.5%

Total Debt

$8.25M

-21.8%

Accounts Receivable

$902.00K

-11.0%

Inventory

$0.00

N/A

Long Term Debt

$4.10M

-30.0%

Short Term Debt

$4.15M

-11.6%

Return on Assets

-4.20%

N/A

Return on Invested Capital

8.40%

N/A

Free Cash Flow

-$3.84M

+59.6%

Operating Cash Flow

-$3.84M

+59.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MSPRMSP Recovery, Inc.
$0.00+9900.00%
STRMStreamline Health Solutions, Inc.
$5.33+0.00%
ELEVElevation Oncology, Inc.
$0.37-2.12%
ELUTElutia Inc
$0.74-4.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About RNLX

What is the current price of Renalytix Plc?

Renalytix Plc is trading at N/A per share.

What is the 52-week range for Renalytix Plc?

Over the past 52 weeks, Renalytix Plc has traded between N/A and N/A.

How much debt does Renalytix Plc have?

As of the most recent reporting period, Renalytix Plc reported total debt of $8.21M.

How much cash does Renalytix Plc have on hand?

Renalytix Plc reported $9.21M in cash and cash equivalents in its most recent financial results.

What is Renalytix Plc’s dividend yield?

Renalytix Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.